Which of the following agent is safest for treating chloroquine resistant malaria in a 26 year old primigravida?
**Core Concept**
The question tests knowledge of antimalarial drugs, specifically those used for treating chloroquine-resistant malaria in pregnant women. **Malaria in pregnancy** is a significant concern due to the increased risk of severe disease and adverse outcomes.
**Why the Correct Answer is Right**
Since the correct answer is not provided, general principles will be discussed. For chloroquine-resistant malaria in pregnancy, especially in the first trimester, the safest options are crucial. Typically, **quinine** plus **clindamycin** or **artesunate** (in areas where it's recommended for pregnant women) are considered, but the choice depends on the trimester and local resistance patterns.
**Why Each Wrong Option is Incorrect**
**Option A:** Without knowing the specific option, generally, any drug not recommended in pregnancy due to teratogenic effects or lack of safety data would be incorrect.
**Option B:** Similarly, an option that poses significant risks to the fetus or has not been proven safe in pregnancy would be wrong.
**Option C:** An incorrect choice might be a drug not effective against chloroquine-resistant strains or one that has significant side effects in pregnancy.
**Option D:** This could potentially be the correct answer if it aligns with safe antimalarial therapy in pregnancy, but without the answer, it's speculative.
**Clinical Pearl / High-Yield Fact**
In treating malaria in pregnant women, it's crucial to consider the stage of pregnancy and the resistance pattern of the malaria parasite in the region. **Artemisinin-based combination therapies** are generally avoided in the first trimester due to limited safety data, although they may be used if benefits outweigh the risks.
**Correct Answer:** D. No specific answer provided.